Brexpiprazole ( breks-PIP-rə-zohl; brand name Rexultirecks-UL-tee, previously known as OPC-34712) is a novel atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments f
Additional text has been truncated due to copyright reasons. Things without URLs and private things don't get truncated.
No Things found. Mr_Howie_Kalish hasn't shared anything.